Figure 1. (B) Pie charts showing study reproducibility for each type of the experiment (laboratory, cell type, or study type: 2D=hepatocyte monolayer cultures, 3D=LAMPS chips). Colors depict overall study reproducibility score (green=excellent, yellow=acceptable, red=poor). See details of each experiment and study reproducibility for each parameter in Supplemental Figure X.
| View/Edit | Study Name | Start Date | Study Types | Experimental Models | Model Types | Disease(s) | Data Points | Data Points (omic) | Images | Videos | Plate Maps | Plate Reader Files | Supporting Data Files | Description | Reproducibility Status | Center | Data Entry | Review | Sign Off Date | Data Provider | ID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| View/Edit | UPLiver_Tier2a2b_2D | 2018-08-15 | CC | SQL-SAL [TAMU 96w] | Static-2D | -No Diseases- | 888 | 0 | 60 | 0 | 0 | 0 | 2 | 2D companion to the UPLiver_Tier2a2b_3D Study This tier of testing was part of the 2D “Baseline” and “Metabolism” studies to measure the secretome and metabolic capacity of cells plated in 2D culture. In this study, 30 wells from a 2D cell culture plate (96-well plate) were plated with iPSC-derived hepatocytes from CDI, as well as supporting cells (LX-2, EA.Hy926, and THP-1). Cultures were treated with either cell culture media (n=10), vehicle (0.1% DMSO, n=10), or a 10uM Terfenadine (n=10). Cells were cultured over 12 days with daily media sampling. Media was tested for Albumin, Urea-Nitrogen, LDH, and TNF-a, as well as the presence of the parent compound (terfenadine), and the major metabolite (fexofenadine). Additionally, viability testing was carried out at endpoint. | TEX-VAL | Michael Castiglione | 4 | 2019-07-11 | Rusyn_TAMU | 224 | |
| View/Edit | UPLiver_Tier2c_3D | 2018-08-31 | TOX | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 2,150 | 0 | 54 | 0 | 0 | 0 | 2 | This tier of testing was part of the 3D “Toxicity” study to measure the effects of drugs on cells seeded in SQL-SAL tissue chips. In this study, 27 chips (Nortis, Inc.) were seeded with iPSC-derived hepatocytes from CDI, as well as supporting cells (LX-2, EA.Hy926, and THP-1) in a layered collagen matrix. Cultures were treated with either a vehicle (0.1% DMSO, n=3), caffeine (600uM, n=3), trovafloxacin (150uM, n=3), troglitazone (28uM, n=3), tolcapone (88uM, n=3), rosiglitazone (0.8uM, n=3), pioglitazone (3uM, n=3), trovaflocacin + LPS (150uM + 1ug/mL, n=3), or LPS (1ug/mL, n=3). Cells were cultured over 10 days with daily media sampling. Media was tested for flow rate, Albumin, Urea-Nitrogen, LDH, and TNF-a, as well as the presence of the parent drug compounds. Additionally, viability testing was carried out at endpoint. | TEX-VAL | Michael Castiglione | 4 | 2019-07-11 | Rusyn_TAMU | 225 | |
| View/Edit | UPLiver_Tier2c_2D | 2018-08-31 | TOX | SQL-SAL [TAMU 96w] | Static-2D | -No Diseases- | 1,946 | 0 | 120 | 0 | 0 | 0 | 2 | 2D companion to the UPLiver_Tier2c_3D Study This tier of testing was part of the 2D “Toxicity” study to measure the effects of drugs on cells plated in 2D culture. In this study, 60 wells from a 2D cell culture plate (96-well plate) were plated with iPSC-derived hepatocytes from CDI, as well as supporting cells (LX-2, EA.Hy926, and THP-1). Cultures were treated with either a vehicle (0.1% DMSO, n=12), caffeine (600uM, n=6), trovafloxacin (150uM, n=6), troglitazone (28uM, n=6), tolcapone (88uM, n=6), rosiglitazone (0.8uM, n=6), pioglitazone (3uM, n=6), trovaflocacin + LPS (150uM + 1ug/mL, n=6), or LPS (1ug/mL, n=6). Cells were cultured over 10 days with daily media sampling. Media was tested for Albumin, Urea-Nitrogen, LDH, and TNF-a, as well as the presence of the parent drug compounds. Additionally, viability testing was carried out at endpoint. | TEX-VAL | Michael Castiglione | 4 | 2019-07-11 | Rusyn_TAMU | 226 | |
| View/Edit | Tier1a_Upitt_3D | 2018-04-19 | CC | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 581 | 0 | 36 | 0 | 0 | 0 | 1 | This tier of testing was part of the 3D “Baseline” study to measure the secretome of cells seeded in the SQL-SAL tissue chip without any treatments. In this study, 6 chips (Nortis, Inc.) were seeded with primary hepatocytes from ThermoFisher, as well as supporting cells (LX-2, EA.Hy926, and THP-1) in a layered collagen matrix. Cells were cultured over 11 days with daily media sampling. Media was tested for flow rate, Albumin, Urea-Nitrogen, LDH, and TNF-a. | TEX-VAL | Admin Sandra Karcher | 4 | 2019-07-11 | Rusyn_TAMU | 147 | |
| View/Edit | Tier1a_Upitt_2D | 2018-04-19 | CC | SQL-SAL [TAMU 96w] | Static-2D | -No Diseases- | 528 | 0 | 205 | 0 | 0 | 0 | 2 | This tier of testing was part of the 2D “Baseline” study to measure the secretome of cells plated in 2D culture without any treatments. In this study, 50 wells from a 2D cell culture plate (96-well plate) were plated in one of two configurations: with (n=30), or without (n=20) a collagen layer over the top of the cell monolayer. Wells were plated with primary hepatocytes from ThermoFisher, as well as supporting cells (LX-2, EA.Hy926, and THP-1). Cells were cultured over 10 days with daily media sampling. Media was tested for Albumin, Urea-Nitrogen, LDH, and TNF-a. It was determined that cells behaved better without the collagen layer on the top, so further 2D studies were carried out without the collagen layer over the cells. | TEX-VAL | Admin Sandra Karcher | 4 | 2019-07-11 | Rusyn_TAMU | 148 | |
| View/Edit | EPA 4 | 2016-10-13 | TOX | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 356 | 0 | 0 | 0 | 0 | 0 | 0 | Eighteen day study assessing toxicity of Erythromycin, Famotidine, Levofloxacin, Rosglitazone, and Trovafloxcin. | UPDDI | Dillon Gavlock | 4 | 2019-07-16 | Taylor_EPA | 122 | |
| View/Edit | Tier1c_Upitt_2D | 2018-08-04 | TOX-CC | SQL-SAL [TAMU 96w] | Static-2D | -No Diseases- | 2,125 | 0 | 120 | 0 | 0 | 0 | 2 | 2D, 96-well based companion study for Tier1c_Upitt_3D This tier of testing was part of the 2D “Toxicity” study to measure the effects of drugs on cells plated in 2D culture. In this study, 60 wells from a 2D cell culture plate (96-well plate) were plated with primary hepatocytes from ThermoFisher, as well as supporting cells (LX-2, EA.Hy926, and THP-1). Cultures were treated with either a vehicle (0.1% DMSO, n=12), caffeine (600uM, n=6), trovafloxacin (150uM, n=6), troglitazone (28uM, n=6), tolcapone (88uM, n=6), rosiglitazone (0.8uM, n=6), pioglitazone (3uM, n=6), trovaflocacin + LPS (150uM + 1ug/mL, n=6), or LPS (1ug/mL, n=6). Cells were cultured over 10 days with daily media sampling. Media was tested for Albumin, Urea-Nitrogen, LDH, and TNF-a, as well as the presence of the parent drug compounds. Additionally, viability testing was carried out at endpoint. | TEX-VAL | Michael Castiglione | 4 | 2019-07-11 | Rusyn_TAMU | 219 | |
| View/Edit | Tier1c_Upitt_3D | 2018-06-23 | TOX-EFF | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 2,696 | 0 | 72 | 0 | 0 | 0 | 2 | This tier of testing was part of the 3D “Toxicity” study to measure the effects of drugs on cells seeded in SQL-SAL tissue chips. In this study, 36 chips (Nortis, Inc.) were seeded with primary hepatocytes from ThermoFisher, as well as supporting cells (LX-2, EA.Hy926, and THP-1) in a layered collagen matrix. Cultures were treated with either a vehicle (0.1% DMSO, n=6), caffeine (600uM, n=4), trovafloxacin (150uM, n=5), troglitazone (28uM, n=6), tolcapone (88uM, n=3), rosiglitazone (0.8uM, n=3), pioglitazone (3uM, n=3), trovaflocacin + LPS (150uM + 1ug/mL, n=3), or LPS (1ug/mL, n=3). Cells were cultured over 10 days with daily media sampling. Media was tested for flow rate, Albumin, Urea-Nitrogen, LDH, and TNF-a, as well as the presence of the parent drug compounds. Additionally, viability testing was carried out at endpoint. Note: This study was carried out in 3 “arms” of testing: A, B, and C as noted on PTMs. | TEX-VAL | Michael Castiglione | 4 | 2019-07-11 | Rusyn_TAMU | 189 | |
| View/Edit | UPLiver_Tier2a2b_3D | 2018-08-15 | CC | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 1,248 | 0 | 26 | 0 | 0 | 0 | 2 | This tier of testing was part of the 3D “Baseline” and “Metabolism” studies to measure the secretome and metabolic capacity of cells seeded in SQL-SAL tissue chips. In this study, 13 chips (Nortis, Inc.) were seeded with iPSC-derived hepatocytes from CDI, as well as supporting cells (LX-2, EA.Hy926, and THP-1) in a layered collagen matrix. Cultures were treated with either cell culture media (n=5), vehicle (0.1% DMSO, n=4), or a 10uM Terfenadine (n=4). Cells were cultured over 12 days with daily media sampling. Media was tested for Albumin, Urea-Nitrogen, LDH, and TNF-a, as well as the presence of the parent compound (terfenadine), and the major metabolite (fexofenadine). Additionally, viability testing was carried out at endpoint. Note that there was a power outage that stalled syringe pumps on days 11-12. | TEX-VAL | Michael Castiglione | 4 | 2019-07-11 | Rusyn_TAMU | 223 |